Raymond James Upgrades Vera Therapeutics to Strong Buy, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse upgraded Vera Therapeutics (NASDAQ:VERA) from Outperform to Strong Buy and increased the price target from $29 to $37.

January 26, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vera Therapeutics was upgraded by Raymond James from Outperform to Strong Buy, with a price target increase from $29 to $37.
Upgrades by analysts, especially to a Strong Buy rating, typically signal confidence in a company's future performance and can lead to increased investor interest. The raised price target further suggests a positive outlook on the stock's value, which may result in a short-term price increase.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100